Transition Therapeutics (TTHI) Provides Positive Results of TT-223 Phase 2 in Type 2 Diabetes Patients
Tweet Send to a Friend
Transition Therapeutics Inc. (NASDAQ: TTHI) today announced the results from a Phase 2 clinical study of gastrin analogue, TT-223, in ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
